Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PHEROZE TAMBOLI and ERIC JONASCH.
PHEROZE TAMBOLI
Connection Strength
2.966
ERIC JONASCH
  1. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
    View in: PubMed
    Score: 0.451
  2. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.144
  3. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.131
  4. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.130
  5. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene. 2016 Mar 24; 35(12):1565-74.
    View in: PubMed
    Score: 0.129
  6. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.129
  7. The impact of FGFR1 and FRS2a expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer. 2015 Apr 18; 15:304.
    View in: PubMed
    Score: 0.128
  8. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol. 2014 Sep; 45(9):1966-72.
    View in: PubMed
    Score: 0.121
  9. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
    View in: PubMed
    Score: 0.115
  10. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer. 2013 Jun; 32(6):303-11.
    View in: PubMed
    Score: 0.109
  11. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.105
  12. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010 Aug; 21(8):1599-1606.
    View in: PubMed
    Score: 0.089
  13. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65.
    View in: PubMed
    Score: 0.089
  14. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
    View in: PubMed
    Score: 0.086
  15. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41.
    View in: PubMed
    Score: 0.078
  16. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265.
    View in: PubMed
    Score: 0.049
  17. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
    View in: PubMed
    Score: 0.046
  18. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
    View in: PubMed
    Score: 0.038
  19. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.037
  20. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.037
  21. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  22. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.034
  23. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
    View in: PubMed
    Score: 0.034
  24. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.033
  25. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.033
  26. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
    View in: PubMed
    Score: 0.032
  27. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.032
  28. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.032
  29. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.032
  30. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.032
  31. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9(2):e89880.
    View in: PubMed
    Score: 0.030
  32. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.029
  33. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res. 2013 May 01; 19(9):2460-72.
    View in: PubMed
    Score: 0.028
  34. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci. 2012 Sep 24; 10(1):56.
    View in: PubMed
    Score: 0.027
  35. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324.
    View in: PubMed
    Score: 0.026
  36. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71.
    View in: PubMed
    Score: 0.024
  37. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053.
    View in: PubMed
    Score: 0.024
  38. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.024
  39. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5.
    View in: PubMed
    Score: 0.023
  40. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81.
    View in: PubMed
    Score: 0.023
  41. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7.
    View in: PubMed
    Score: 0.021
  42. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res. 2009 Jan 01; 15(1):81-90.
    View in: PubMed
    Score: 0.021
  43. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41.
    View in: PubMed
    Score: 0.020
  44. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8.
    View in: PubMed
    Score: 0.020
  45. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900.
    View in: PubMed
    Score: 0.019
  46. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May; 69(5):835-8.
    View in: PubMed
    Score: 0.018
  47. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007 Mar; 177(3):855-60; discussion 860-1.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.